

From: [Do, Yu](#)
To: [James Maloney](#)
Subject: Information Request (Response Due by Thursday, March 21, 2019): Class 2 Resubmission, BL 125590/0, Immune Globulin Intravenous (Human), 10% Liquid, ADMA Biologics, Inc.
Date: Wednesday, March 20, 2019 9:59:00 PM
Attachments: [image001.png](#)
Importance: High

Dear Mr. Maloney:

We are reviewing your resubmission of September 28, 2018, to BL 125590/0 for Immune Globulin Intravenous (Human), 10% Liquid. We have the following comment and request for additional information to continue our review:

The following is our proposed language drafted for a Postmarketing Commitment with regard to BL 125590/0:

ADMA commits to submitting information on the ongoing stability study, SP-BK-3092, annually as a “Postmarketing Commitment – Status Update.” The final stability report will be submitted as a “Postmarketing Commitment – Final Study Report” by June 30, 2020. ADMA will also report any confirmed out-of-specification results at the recommended storage condition from the stability monitoring to the Agency within 45 days of the event(s).

Final Report Submission Date: June 30, 2020

Please inform us in writing, upon review and internal discussion, if you agree with the proposed due date. If not, please state accordingly and suggest alternative date(s) for our consideration.

The review of this submission is ongoing, and issues may be added, expanded upon, or modified as we continue to review this submission. Please submit your response as an amendment to this file (BL 125590/0) by Thursday, March 21, 2019, referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

If we determine that your response to this information request constitutes a major amendment, we will notify you in writing.

The action due date for this file is April 2, 2019.

Please acknowledge receipt of this request and contact me at (240) 402-8343 or Yu.Do@fda.hhs.gov if you have any questions.

Sincerely,

Yu Do, M.S.
Regulatory Project Manager
Office of Tissues and Advanced Therapies
Center for Biologics Evaluation and Research
Office of Medical Products and Tobacco

Food and Drug Administration
(240) 402-8343
Yu.Do@fda.hhs.gov



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."